Pediatric Cancer Patients Vaccinated Against SARS-CoV-2 – A Clinical and Laboratory Follow-Up
Abstract Background Vaccination against SARS-CoV-2 is recommended for cancer patients. However, long-term data on the effectiveness in the pediatric setting are lacking. Methods Pediatric patients < 18 years on active treatment for cancer and without prior SARS-CoV-2 infection received three doses of an mRNA vaccine. The clinical course, and the humoral and cellular immunity were evaluated at the end of the follow-up period of ≥ 1 year after the third dose of vaccine. Results SARS-CoV-2 infection occurred in 17 of 19 analyzed patients (median age 16.5 years) during the follow-up period (median 17 months), but no severe symptoms were seen. ≥1 year after the last SARS-CoV-2 antigen exposure, 4 of 17 patients had received the recommended booster vaccine. At the end of the follow-up period, all evaluable 15 patients had anti-SARS-CoV-2 receptor-binding domain IgG antibodies. Twelve of the 15 patients had neutralizing antibody titers ≥ 1:10 against the Delta variant, 12/15 and 13/15 against the BA.1 and BA.5 variant, respectively. Specific T cells against SARS-CoV-2 antigens were seen in 9/13 patients. Conclusions Most SARS-CoV-2 vaccinated pediatric cancer patients had mild infections and limited interest in booster vaccination. One year after the last antigen exposure, which was mostly an infection, humoral immune responses remained strong. German Clinical Trials Register DRKS00025254, May 26, 2021.
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ResearchSquare.com - (2024) vom: 15. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Siebald, Benjamin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-3386102/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA041092775 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA041092775 | ||
| 003 | DE-627 | ||
| 005 | 20240316173938.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231006s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-3386102/v1 |2 doi | |
| 035 | |a (DE-627)XRA041092775 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-3386102/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Siebald, Benjamin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pediatric Cancer Patients Vaccinated Against SARS-CoV-2 – A Clinical and Laboratory Follow-Up |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Vaccination against SARS-CoV-2 is recommended for cancer patients. However, long-term data on the effectiveness in the pediatric setting are lacking. Methods Pediatric patients < 18 years on active treatment for cancer and without prior SARS-CoV-2 infection received three doses of an mRNA vaccine. The clinical course, and the humoral and cellular immunity were evaluated at the end of the follow-up period of ≥ 1 year after the third dose of vaccine. Results SARS-CoV-2 infection occurred in 17 of 19 analyzed patients (median age 16.5 years) during the follow-up period (median 17 months), but no severe symptoms were seen. ≥1 year after the last SARS-CoV-2 antigen exposure, 4 of 17 patients had received the recommended booster vaccine. At the end of the follow-up period, all evaluable 15 patients had anti-SARS-CoV-2 receptor-binding domain IgG antibodies. Twelve of the 15 patients had neutralizing antibody titers ≥ 1:10 against the Delta variant, 12/15 and 13/15 against the BA.1 and BA.5 variant, respectively. Specific T cells against SARS-CoV-2 antigens were seen in 9/13 patients. Conclusions Most SARS-CoV-2 vaccinated pediatric cancer patients had mild infections and limited interest in booster vaccination. One year after the last antigen exposure, which was mostly an infection, humoral immune responses remained strong. German Clinical Trials Register DRKS00025254, May 26, 2021 | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Groll, Andreas H. |4 aut | |
| 700 | 1 | |a Salou, Sarah |4 aut | |
| 700 | 1 | |a Boldt, Andreas |4 aut | |
| 700 | 1 | |a Seiffert, Sabine |4 aut | |
| 700 | 1 | |a Sack, Ulrich |4 aut | |
| 700 | 1 | |a Reemtsma, Judith |4 aut | |
| 700 | 1 | |a Jassoy, Christian |4 aut | |
| 700 | 1 | |a Klusmann, Jan-Henning |4 aut | |
| 700 | 1 | |a Ciesek, Sandra |4 aut | |
| 700 | 1 | |a Hoehl, Sebastian |4 aut | |
| 700 | 1 | |a Lehrnbecher, Thomas |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2024) vom: 15. März |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:03 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00520-024-08422-5 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-3386102/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 03 | ||